The "Mar-A-Lago Accord" Is Now Underway
The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)
Financials
| Curr Year EPS Estimate | 3.94 |
| Next Quarter EPS Estimate | 0.54 |
| Profit Margin | -12.96% |
| Operating Margin | -7.32 |
| Return on Assets | -0.03 |
| Return on Equity | -2.58 |
| Revenue | 2.5B |
| Earnings Per Share | -2.49 |
| Revenue Per Share | 19.01 |
| Gross Profit | 2,059,246,976 |
| Quarterly Revenue Growth | 0.17 |
General
| Name | Alnylam Pharmaceuticals Inc |
| Ticker | ALNY |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Currency | USD |
| Country | USA |
| Fiscal Year End | December |
| Full Time Employees | 2,230 |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Earnings
Donald Trump's Approval Rating Crashes to Record Low — Here's What's Driving the Decline
According to the recent YouGov/Economist poll, President Trump's approval rating has taken a nosedive, reaching its lowest point in his second term.
America Has A New No. 1 Beer — And It's Got Bud Light DNA
When it comes to beer in the United States, there's a new bestselling brand.
[Revealed] Trump's Next AI Executive Orders? - Ad
A White House insider with direct ties to Trump's inner circle just revealed what he calls "Manhattan II" - a potential $2.2 trillion AI initiative set to launch as soon as Oct 15. He says this could mirror past U.S. projects that minted fortunes - with small firms soaring 5,000% to 10,000% over two decades. And now he's giving away his #1 stock pick for free before the deadline.
Gavin Newsom Faces Backlash From Trump Officials After Controversial Kristi Noem Post: 'Reads Like A Threat. This Is Ugly'
Controversial tweet by Gov. Newsom targeting Secretary Noem sparks federal backlash and criticism from Trump allies and officials.
3 Gold Mining Stocks Shine As Prices Hit Records
Gold mining stocks Anglogold Ashanti, Coeur Mining, and New Gold join the top 10% for quality as gold prices hit fresh highs.
What's inside Elon's building in Memphis will shock you - Ad
Inside Elon Musk's Memphis site lies a supercomputer built to power the world's first superhuman AI. It could make Elon a trillionaire - and new millionaires, too. With just $500, you could get in before the November 1st funding window closes.
Rigetti's Quantum Leap Powers ETF Momentum
Rigetti Computing has seen a 3,900% rise in the past year, attracting attention from investors interested in ETFs.
Ben & Jerry's Co-Founder Resigns In Protest As Politics Continue To Influence Corporate Exits
Jerry Greenfield, of Ben & Jerry's fame, didn't resign over personal controversy—he quit because his company stopped being political enough.
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Australia warns social media platforms against age verification for all ahead of a ban on children
MELBOURNE, Australia (AP) — Australian authorities said Tuesday that should not demand age verification for all account holders starting from December, when a having accounts goes into effect in the country.
Steve Jobs Once Paused For 18 Seconds To Answer A Student's Simple Question: Here Is What The Apple Co-Founder Said
Steve Jobs took an 18-second pause before answering a question, showing his habit of thinking first. He values long-term talent development.
Jeff Brown: "I Warned You About Elon Musk..." - Ad
While everyone said Tesla was finished... On June 11, I predicted that we were on the cusp of one of the most shocking comebacks in Wall Street history. Sure enough, Tesla is now up 25% and recovered all 2025 losses. But this is just the beginning of Elon's $25 trillion breakthrough.
Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients
Johnson & Johnson's Tecvayli-Darzalex regimen showed 100% response rates and high MRD negativity in newly diagnosed multiple myeloma patients.
What are Nexstar and Sinclair, the ABC affiliate owners who issued statements against Jimmy Kimmel
NEW YORK (AP) — spoke out against late night ahead of over comments he made about the killing of . Their comments highlight the influence local TV station owners have on national broadcasters such as Disney-owned ABC.
Nvidia Is About to Shock the World: October 23rd - Ad
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%, is warning everyone to... Mark this date on your calendar: October 23rd! That's when Nvidia could help send shares of this Elon Musk supplier skyrocketing higher.
New England's shrimp industry is struggling, with fishermen catching few in 2025
PORTLAND, Maine (AP) — There's an effort underway to bring New England shrimp back to seafood customers — but fishermen have found few of the crustaceans, and the fishing industry that harvests them may face an even longer shutdown.
Costco Wholesale, Concentrix And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Is Elon's Empire Crumbling? - Ad
Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after October 23rd, it may be too late.
Warner Bros, Oracle, And Micron Technology Are Among The Top 10 Large-Cap Gainers Last Week (Sep. 8 - Sep. 12): Are The Others In Your Portfolio?
Deal buzz, analyst upgrades, and AI momentum drove top weekly gainers—led by Warner Bros., Oracle, and Micron—across large-cap tech and media.
In coastal Ghana, female oyster farmers try to save an old practice threatened by climate change
TSOKOMEY, Ghana (AP) — Beatrice Nutekpor weaves through the mangroves in Tsokomey community, just outside of Ghana’s capital of Accra, . It’s a family tradition she’s been doing since she was 15. Now 45, she is struggling to sustain the practice and pass it to her daughter.
Elon's $25 Trillion Confession - Ad
Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.
Opendoor Stock Rallies On Expansion And Short Squeeze Hopes
Opendoor stock rallied on Wednesday after it announced an expansion of U.S. operations, but it didn't specify which operations.
US To Impose $100,000 Annual Fee On H-1B Visas As Analysts Warn Trump Risks 'Taxing Away' America's Innovation Edge
The Trump administration's plan to impose a $100,000 annual fee on H-1B visas could reshape tech hiring, strain talent pipelines from India and China, and risk driving innovation overseas, analysts warn.
Is This Elon's Worst Nightmare? - Ad
Elon's empire looks doomed - crashing sales, lost tax credits, and media backlash. But behind the scenes, Tesla is about to unleash a breakthrough Forbes calls a "multi-trillion-dollar opportunity." It's not the end - it's the start of a 25,000% AI comeback.
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and consistent safety profiles.
Warsaw turns to Ukraine for drone warfare expertise after Russian drones enter Polish airspace
KYIV, Ukraine (AP) — Poland’s defense chief traveled to Kyiv on Thursday in search of Ukrainian help in developing his country's drone warfare capabilities, just over a week after and exposed to drone warfare.
Gold Is Being Reintroduced Into the Monetary System - Ad
While the media focuses on political scandals, inflation and coming up with ridiculous acronyms "TACO"... Smart money is tracking a far bigger shift: a gold revaluation is quietly underway. Garrett Goggin, CFA, says this could trigger 100X moves in select miners - and he's identified four with the biggest upside.
Larry Ellison: College Dropout And World's 2nd Richest Man
Here are five surprising facts you might not know about Larry Ellison.
Pilgrims turn Spain's Santiago de Compostela into the world's latest overtourism flashpoint
SANTIAGO DE COMPOSTELA, Spain (AP) — While some Barcelona residents sought to repel a tsunami of tourists , a neighborhood association in Santiago de Compostela opted for a friendlier approach: a guide to good manners for visitors to their town, the endpoint of the Catholic world's most famous pilgrimage.
The "Mar-A-Lago Accord" Is Now Underway - Ad
The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)
Why Redwire Stock Is Gaining Today
Redwire climbs about 4% after subsidiary Edge Autonomy wins a European NATO ally contract to supply Stalker Group 2 reconnaissance drone.
Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
[Revealed] Trump's Next AI Executive Orders? - Ad
A White House insider with direct ties to Trump's inner circle just revealed what he calls "Manhattan II" - a potential $2.2 trillion AI initiative set to launch as soon as Oct 15. He says this could mirror past U.S. projects that minted fortunes - with small firms soaring 5,000% to 10,000% over two decades. And now he's giving away his #1 stock pick for free before the deadline.
Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio?
Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.
Bitcoin Unmoved By Fed Rate Cut; Ethereum, XRP, Dogecoin Spike: Analyst Says BTC Should See $120,000 By End Of Week If 'All Goes To Plan'
Bitcoin failed to break out of its range, but other major coins rose on Wednesday as the Federal Reserve implemented its first interest rate cut of the year.
What's inside Elon's building in Memphis will shock you - Ad
Inside Elon Musk's Memphis site lies a supercomputer built to power the world's first superhuman AI. It could make Elon a trillionaire - and new millionaires, too. With just $500, you could get in before the November 1st funding window closes.
US To Set $5 Billion Critical Minerals Fund
US to launch $5 billion fund for critical minerals, in partnership with Orion Resource Partners and other investors. Aimed at reducing reliance on Chinese supply chains and securing long-term resources.
Trump's $17 Trillion New Investments Claim 'Clearly' Not True, Says Peter Schiff: GDP Growth Would 'Explode by Roughly 50%' If Factual
Economist Peter Schiff is calling out President Donald Trump's claims regarding $17 trillion in new investments flowing into the U.S. economy.
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Supreme Court will weigh expanding Trump’s power to shape agencies by overturning 90-year-old ruling
WASHINGTON (AP) — said Monday it will consider expanding President Donald Trump's power to shape independent agencies by overturning a nearly century-old decision limiting when presidents can fire board members.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.